Cardinal Health products won’t be in Cleveland medical mart (or any other)

Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health (NYSE:CAH) has had an apparent change of opinion.The giant drug distributor – and Ohio’s largest company – does not plan to lease space in the planned Cleveland medical mart or its counterpart in Nashville, spokeswoman Corey Kerr said. So don’t expect [...]

[Read more of this report]


Will Cardinal Health say no to the ‘Dead Man Walking’ nun?

The capital punishment-opposing nun prominently featured in the movie “Dead Man Walking” has asked Cardinal Health (NYSE: CAH) to recall a drug that’s used in the execution of prisoners.But Sister Helen Prejean isn’t likely to be pleased with the response from the Dublin, Ohio-based pharmaceuticals distributor. A Cardinal spokeswoman was asked multiple times whether the [...]

[Read more of this report]


Cardinal Health ups guidance on strong pharma sales

Medical products supplier Cardinal Health (NYSE:CAH) raised its full-year earnings expectations, driven in part by a 25 percent increase in third-quarter profits in its pharmaceutical business.Dublin, Ohio-based Cardinal now expects adjusted full-year earnings per share from continuing operations between $2.61 and $2.67, according to a statement from the company. CEO George Barrett cited strong year-to-date [...]

[Read more of this report]


Cardinal Health board member steps down

After a little more than a year on the job, a Cardinal Health (NYSE:CAH) board member is stepping down for health reasons.Dr. James Mongan’s resignation comes “due to health-related reasons,” and “is not the result of any disagreement with [Cardinal] on any matter relating to the [its] operations, policies or practices,” according to a regulatory [...]

[Read more of this report]


‘Generic wave’ to drive Cardinal Health’s profitability in coming years

Cardinal Health (NYSE:CAH) and pharmaceuticals distributors of its ilk will have few better friends over the coming years than generic drugs.The so-called “generic wave” — created by scores of brand-name drugs whose patents are expiring between this year and 2015 — is expected to be a huge boon to drug wholesalers like Dublin, Ohio-based Cardinal, [...]

[Read more of this report]


Neoprobe looking ripe for acquisition; any takers?

As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) marches toward FDA approval of its “game-changing” radiopharmaceutical Lymphoseek and its share price continues to climb, many of the company’s shareholders are likely wondering when they’ll get the chance to cash out.There’s certainly plenty of investor interest in the company. Neoprobe’s shares are up a whopping 77 [...]

[Read more of this report]


Cardinal Health raises 2011 guidance after ‘very positive’ Q2 results

Drug distributor Cardinal Health (NYSE:CAH) raised its earnings outlook for 2011 after it reported an 11 percent increase in the profits of its pharmaceuticals business unit in its fiscal second quarter.

[Read more of this report]


Generic drugs to fuel growth for Cardinal Health, other pharma wholesalers

As generic drugs increasingly replace brand names in the coming years, pharmaceuticals wholesalers like Cardinal Health (NYSE:CAH) will see their operating profits rise “dramatically,” according to a report from Barclays Capital.

[Read more of this report]


Federal lobbying spending: Cardinal Health led Ohio health groups in 2010

Cardinal Health (NYSE: CAH), Ohio’s largest company by revenues, led the state’s health organizations in federal lobbying spending last year at nearly $1.3 million. Cardinal, a pharmaceuticals distributor and medical products supplier, upped its federal lobbying spending by 39 percent over the prior year, publicly filed lobbying reports revealed.

[Read more of this report]


Cardinal Health’s dependence on top customers leaves it ’vulnerable’

Cardinal Health (NYSE:CAH) renewal of a key drug distribution contract with Walgreen Co. earlier this month brings renewed focus on just how heavily reliant Cardinal is on its top two customers. In Cardinal’s fiscal 2010, Walgreen (24 percent) and CVS (22 percent) combined for a 46 percent share of revenues. That’s up from a combined 43 percent in 2008. Adam Fein, a pharmaceutical industry consultant with Pembroke Consulting, stated on his blog Drug Channels: “The data show a company that’s increasingly at the mercy of its two dominant customers.”

[Read more of this report]


« Newer PostsOlder Posts »

Be a Thought Leader: Join MedCitizens

Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.

Click to login or learn more

MedCity Jobs Board


MedCity Whitepapers

Real Time Web Analytics